Pathway based prognostic gene expression profile of buccal and gingivo-buccal oral squamous cell carcinoma in smokeless tobacco chewers

Head & Neck ◽  
2018 ◽  
Author(s):  
Kavitha Prasad ◽  
Roopa Rao ◽  
Dominic Augustine ◽  
Samudrala Venkatesiah Sowmya ◽  
Vanishri Haragannavar ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Squamous Cell ◽  
Smokeless Tobacco ◽  
Prognostic Gene

Gene Expression Profile in Oral Squamous Cell Carcinoma: A Pilot Study

2005 ◽  
Vol 63 (6) ◽  
pp. 786-792 ◽  
Author(s):  
José Manuel Somoza-Martín ◽  
Abel García-García ◽  
Francisco Barros-Angueira ◽  
Eva Otero-Rey ◽  
María Torres-Español ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Pilot Study ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Squamous Cell

Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma

2011 ◽  
Vol 223 (4) ◽  
pp. 459-469 ◽  
Author(s):  
Kue Peng Lim ◽  
Nicola Cirillo ◽  
Yazan Hassona ◽  
Wenbin Wei ◽  
Johanna K Thurlow ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Squamous Cell ◽  
Tumour Progression

Association between gene expression profile and tumor invasion in oral squamous cell carcinoma

2004 ◽  
Vol 154 (1) ◽  
pp. 27-35 ◽  
Author(s):  
Gokce A. Toruner ◽  
Celal Ulger ◽  
Mualla Alkan ◽  
Anthony T. Galante ◽  
Joseph Rinaggio ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Squamous Cell ◽  
Tumor Invasion

scholarly journals Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma

2011 ◽  
Vol 40 (4) ◽  
pp. 1180-1188 ◽  
Author(s):  
CAMILA OLIVEIRA RODINI ◽  
FLÁVIA CALÓ AQUINO XAVIER ◽  
KATIÚCIA BATISTA SILVA PAIVA ◽  
MARIA FERNANDA DE SOUZA SETÚBAL DESTRO ◽  
RAQUEL AJUB MOYSES ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Gene Expression Profile ◽  
Prognostic Marker ◽  
Expression Profile ◽  
Squamous Cell ◽  
Homeobox Gene

scholarly journals Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients

2021 ◽  
Author(s):  
Sherri Borman ◽  
Jeff Wilkinson ◽  
Lauren Meldi-Sholl ◽  
Clare Johnson ◽  
Kelsey Carter ◽  
...  
Keyword(s):  
Gene Expression ◽  
Squamous Cell Carcinoma ◽  
High Risk ◽  
Cell Carcinoma ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Risk Class ◽  
Class 1

Abstract Background To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the DecisionDx-SCC assay, a prognostic 40-gene expression profile (40-GEP) test, was developed and validated. The 40-GEP assay utilizes RT-PCR gene expression analysis on primary tumor biopsy tissue to evaluate the expression of 34 signature gene targets and 6 normalization genes. The test provides classifications of low risk (Class 1), moderate risk (Class 2A), and high risk (Class 2B) of metastasis within 3 years of diagnosis. The primary objective of this study was to validate the analytical performance of the 40 gene expression signature. Methods The repeatability and reproducibility of the 40-GEP test was evaluated by performance of inter-assay, intra-assay, and inter-operator precision experiments along with monitoring the reliability of sample and reagent stability for class call concordance. The technical performance of clinical orders from September 2020 through July 2021 for the 40-GEP test was assessed. Results Patient hematoxylin and eosin (H&E) stained slides were reviewed by a board-certified pathologist to assess minimum acceptable tumor content. Class specific controls (Class 1 and Class 2B) were evaluated with Levey Jennings analysis and demonstrated consistent and reproducible results. Inter-assay, inter-operator and intra-assay concordance were all ≥90%, with short-term and long-term RNA stability also meeting minimum concordance requirements. Of the 2,446 orders received, 93.4% remained eligible for testing, with 96.8% of all tested samples that completed the assay demonstrating actionable class call results. Conclusion DecisionDx-SCC demonstrates a high degree of analytical precision, yielding high concordance rates across multiple performance experiments, along with exhibiting robust technical reliability on clinical samples.

Sign in / Sign up

Export Citation Format

Share Document